Amarin Corp Plcuk (AMRN) Change in Receivables (2013 - 2026)
Amarin Corp Plcuk (AMRN) posted quarterly Change in Receivables of -$18.8 million for Q1 2026, down 20.82% YoY from -$23.7 million in Q1 2025, and down 3837.32% sequentially from -$477000.0 in Q4 2025.
Amarin Corp Plcuk (AMRN) Change in Receivables (2013 - 2026) Analysis & Trends
Amarin Corp Plcuk has disclosed Change in Receivables across 14 years of filings, most recently posting -$18.8 million for Q1 2026.
- In Q1 2026, Change in Receivables fell 20.82% year-over-year to -$18.8 million; the TTM figure through Mar 2026 stood at $1.3 million (up 114.52% YoY), while the FY2025 annual figure was $4.6 million, up 140.35% from the prior year.
- Change in Receivables slipped to -$18.8 million in Q1 2026, from -$477000.0 in the prior quarter.
- Over the last five years, Change in Receivables for AMRN reached as high as $33.7 million in Q2 2022 and fell as low as -$53.4 million in Q1 2022.
- The 5-year median for Change in Receivables is -$330000.0 (2023), against an average of -$3.3 million.
- The widest YoY moves for Change in Receivables: up 175.05% in 2024, down 3248.18% in 2024.
- A 5-year view of Change in Receivables shows it stood at $7.6 million in 2022, then jumped by 46.67% to $11.2 million in 2023, then slipped by 13.67% to $9.6 million in 2024, then sank by 104.95% to -$477000.0 in 2025, then plunged by 3837.32% to -$18.8 million in 2026.
- According to Business Quant data, Change in Receivables over the past three periods registered -$18.8 million, -$477000.0, and $8.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | - |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 595.00 Mn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | -87.00 Mn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | - |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | - |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | -413.00 Mn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | -134.00 Mn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | - |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Amarin Corp Plcuk | 5.17 Bn | 5.00 Bn | 17.77 Mn | -18.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -18.78 Mn |
| Mar 31, 2026 | -18.78 Mn |
| Dec 31, 2025 | -477,000.00 |
| Dec 31, 2025 | -477,000.00 |
| Sep 30, 2025 | 8.18 Mn |
| Sep 30, 2025 | 8.18 Mn |
| Jun 30, 2025 | 12.40 Mn |
| Jun 30, 2025 | 12.40 Mn |
| Mar 31, 2025 | -15.55 Mn |
| Mar 31, 2025 | -15.55 Mn |
| Dec 31, 2024 | 9.64 Mn |
| Dec 31, 2024 | 9.64 Mn |
| Sep 30, 2024 | -11.05 Mn |
| Sep 30, 2024 | -11.05 Mn |
| Jun 30, 2024 | 7.89 Mn |
| Jun 30, 2024 | 7.89 Mn |
| Mar 31, 2024 | -17.76 Mn |
| Mar 31, 2024 | -17.76 Mn |
| Dec 31, 2023 | 11.16 Mn |
| Dec 31, 2023 | 11.16 Mn |